Netramark Holdings Inc (TSE:AIAI) has released an update.
NetraMark Holdings Inc., a leader in AI-driven clinical trial analytics, has secured a fourth contract with a major biopharmaceutical firm to enhance trial insights using their proprietary NetraAI technology. The AI will analyze trial data to improve patient selection and identify subpopulations affected by treatments, aiming to make trials more efficient and potentially accelerate patient access to therapies. This collaboration highlights NetraMark’s growing influence in transforming clinical trial analysis and patient segmentation.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.
